Literature DB >> 31157079

Stability of prostaglandin E1 solutions stored in polypropylene syringes for continuous intravenous administration to newborns.

David Palmero1,2, Emilienne Chavan1,2, Markoulina Berger-Gryllaki1, Jean-François Tolsa3, Ermindo R Di Paolo1, André Pannatier1,2, Hugues Henry4, Farshid Sadeghipour1,2.   

Abstract

OBJECTIVE: We aimed to monitor the physicochemical stability of prostaglandin E1 (PGE1) 1.5 and 15 µg/mL in 10% dextrose stored in polypropylene syringes.
METHODS: We developed a liquid chromatography-high resolution mass spectrometry (LC-HRMS) method to detect and quantify levels of PGE1. Method selectivity was performed with a mixture of PGE1 and its degradation products. Forced degradation tests were performed to determine which degradation products were most likely to form. PGE1 injection solutions in 10% dextrose were stored in unprotected and shielded-from-light polypropylene syringes in a climatic chamber. Samples were taken immediately after preparation (T0) and after 24, 48, 72 and 168 hours for analysis. PGE1 solutions were considered stable if ≥90.0% of the initial concentration was retained.
RESULTS: The LC-HRMS method was validated in the range of 0.086-0.200µg/mL PGE1 with trueness values between 98.2% and 100.3%, and repeatability and intermediate precision values of <2.2%and <4.7%, respectively. The quantification and detection limits of the method were 0.086 and 0.026µg/mL, respectively. PGE1 and its degradation products were resolved chromatographically. PGE1 injection solutions were≥90.0%stable after 48hours in unprotected from light (UPL) syringes. The solutions remained clear without precipitation, colour or pH modification and subvisible particles within the permitted levels. Prostaglandin A1 was the sole degradation product observed.
CONCLUSIONS: A LC-HRMS method to evaluate PGE1 stability in a 10% dextrose was developed and validated. PGE1 1.5 and 15µg/mL in 10% dextrose solution are stable for 48hours when stored at 30ºC in UPL polypropylene syringes.

Entities:  

Keywords:  alprostadil; drug stability; intensive care unit; liquid chromatography; mass spectrometry; neonatal; newborn; prostaglandins E

Year:  2017        PMID: 31157079      PMCID: PMC6319414          DOI: 10.1136/ejhpharm-2017-001205

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  24 in total

1.  Stability evaluation of a prostaglandin E1 saline solution packed in insulin syringes.

Authors:  R A Uebel; C A Wium; A C Schmidt
Journal:  Int J Impot Res       Date:  2001-02       Impact factor: 2.896

Review 2.  Adverse events in drug administration: a literature review.

Authors:  Gerry Armitage; Helen Knapman
Journal:  J Nurs Manag       Date:  2003-03       Impact factor: 3.325

3.  Unlicensed and off-label drug use in a Swiss paediatric university hospital.

Authors:  Ermindo R Di Paolo; Hans Stoetter; Jacques Cotting; Peter Frey; Mario Gehri; Maja Beck-Popovic; Jean-François Tolsa; Sergio Fanconi; André Pannatier
Journal:  Swiss Med Wkly       Date:  2006-04-01       Impact factor: 2.193

4.  Harmonization of strategies for the validation of quantitative analytical procedures. A SFSTP proposal--Part I.

Authors:  Ph Hubert; J-J Nguyen-Huu; B Boulanger; E Chapuzet; P Chiap; N Cohen; P-A Compagnon; W Dewé; M Feinberg; M Lallier; M Laurentie; N Mercier; G Muzard; C Nivet; L Valat
Journal:  J Pharm Biomed Anal       Date:  2004-11-15       Impact factor: 3.935

5.  Stability of prostaglandin E1 and dinoprostone (prostaglandin E2) under strongly acidic and basic conditions.

Authors:  R G Stehle; T O Oesterling
Journal:  J Pharm Sci       Date:  1977-11       Impact factor: 3.534

6.  Describing nurses' work: combining quantitative and qualitative analysis.

Authors:  Laurie D Wolf; Patricia Potter; Jennifer A Sledge; Stuart B Boxerman; Deborah Grayson; Bradley Evanoff
Journal:  Hum Factors       Date:  2006       Impact factor: 2.888

Review 7.  Optimal timing for intravenous administration set replacement.

Authors:  D Gillies; L O'Riordan; M Wallen; A Morrison; K Rankin; S Nagy
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

8.  Jet nebulization of prostaglandin E1 during neonatal mechanical ventilation: stability, emitted dose and aerosol particle size.

Authors:  Beena G Sood; Jennifer Peterson; Monica Malian; Robert Galli; Maria Geisor-Walter; Jon McKinnon; Jody Sharp; Krishna Rao Maddipati
Journal:  Pharmacol Res       Date:  2007-10-02       Impact factor: 7.658

9.  Simultaneous determination of prostaglandins E1, A1, and B1 by reversed-phase high-performance liquid chromatography for the kinetic studies of prostaglandin E1 in solution.

Authors:  K C Lee; P P DeLuca
Journal:  J Chromatogr       Date:  1991-08-30

10.  Prostaglandin E(1)-based vasoactive cocktails in erectile dysfunction: how environmental conditions affect PGE(1) efficacy.

Authors:  A Bertaccini; R Gotti; M Soli; F Carparelli; R Ceccarelli; V Cavrini; G Martorana
Journal:  Urol Int       Date:  2002       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.